3月5日 - ** 制药公司BioXcel Therapeutics BTAI.O的股价盘前上涨23%至2.03美元
** 该公司称其实验性药物BXCL501在一项针对80名成年人的中期研究中帮助缓解了30%以上的阿片类药物戒断症状
** 补充说，BXCL501 的疗效优于lofexidine，后者是一种治疗戒断症状的非阿片类药物，每天服用四次
** 还指出 BXCL501 与洛非西定相比副作用较少，包括低血压发生率较低和未报告镇静现象
** 2025 年 BTAI 下降了约 73%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.